Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Instagram Outage Disrupts Thousands of U.S. Users 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
PARIS and BOSTON, Aug. 30, 2016 -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announced CEO Miguel Sieler will present at the 18th Annual Rodman & Renshaw Global Investment Conference and Bio Europe 2016.
The Rodman & Renshaw Global Investment Conference, being held September 11-13 in New York, NY, will host over 265 public and private companies, and several thousand attendees. The conference will bring together a vast audience of financial and strategic investors with growth companies in the fields of healthcare, natural resources, technology, media and telecommunications, and cleantech. In addition to corporate presentations, the conference facilitates one-on-one meetings with members of the investment community.
Miguel Sieler, CEO of Neovacs, will present the company at Rodman & Renshaw on Monday September 12, from 10:50 to 11:15 am ET at the New York Palace Hotel, on the fourth floor in the Louis Room.
Neovacs will also present at Bio Europe, which will take place November 7-9 in Cologne, Germany. This conference is one of the world’s most important meetings for the biotech industry. This year the Bio Europe event will draw over 3,500 attendees from 60 countries, representing 1,800 companies. It will provide Neovacs with the opportunity to meet with a vast audience of financial and strategic investors, as well as potential high-level partners.
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts NEOVACS – Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 [email protected] Investor Relations / Financial Communication Germany – MC Services Raimund Gabriel +49-89-21-02-28-30 [email protected] Press / U.S. Inquiries – The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 [email protected] / [email protected]
